Page last updated: 2024-09-03

fosamprenavir and HIV Infections

fosamprenavir has been researched along with HIV Infections in 97 studies

Research

Studies (97)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	68 (70.10)	29.6817
2010's	29 (29.90)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Di Nicola, M; Falasca, K; Pizzigallo, E; Ucciferri, C; Vecchiet, J; Vignale, F	1
Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D	1
DeJesus, E; Edelstein, H; Felizarta, F; Ha, B; Hao, R; Huhn, G; Kumar, P; Pappa, K; Ross, L; Sloan, L; Small, CB; Stancil, B	1
Cassim, H; Cheng, K; Cotton, M; Ford, SL; Garges, HP; Givens, N; Lou, Y; Pavía-Ruz, N; Perger, T; Ross, LL; Sievers, J; Wire, MB	1
Cheng, K; Cotton, M; Duiculescu, D; Ford, SL; Fortuny, C; Garges, HP; Givens, N; Lou, Y; Perger, T; Ross, LL; Sievers, J; Tamarirt, DP; Wire, MB	1
Degli Antoni, A; Ferrari, C; Fragola, V; Manfredi, R; Weimer, LE	1
Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK	1
Duong, T; Ene, L; Galli, L; Giaquinto, C; Goetghebuer, T; Judd, A; Noguera Julian, A; Pimenta, JM; Ramos Amador, JT; Thorne, C	1
Barbour, AM; Gibiansky, L; Wire, MB	1
Cerini, C; Cozzi-Lepri, A; d'Arminio Monforte, A; Giralda, M; Nasta, P; Pimenta, JM; Salmon, D; Winnock, M	1
Calza, L; Chiodo, F; Manfredi, R; Pocaterra, D	1
Adani, GL; Bresadola, V; Furlanut, M; Londero, A; Pavan, F; Pea, F; Tavio, M; Viale, P	1
Ait-Khaled, M; Antoun, Z; Calvez, V; Flandre, P; Katlama, C; Marcelin, AG; Molina, JM; Raffi, F; Yeni, P	1
Burty, C; Christian, B; Ghomari, K; May, T; Pavel, S; Pouaha, J; Rabaud, C; Vermersch, A; Yazdanpanah, Y	1
Bonora, S; Carosi, G; de Requena, DG; Gatti, F; Loregian, A; Matti, A; Nasta, P; Pagni, S; Palù, G; Parisi, SG; Prestini, K; Puoti, M	1
Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V	1
Gills Ray, VL; Lee, H; Silkiss, RZ	1
Corsini, F; Lanzafame, M; Lattuada, E	1
DeJesus, E; Hicks, CB; Lancaster, CT; Liao, Q; Pakes, GE; Pappa, KA; Ross, LL; Sension, MG; Sloan, LM; Wohl, DA	1
Aboulker, JP; Bentata, M; Brun-Vézinet, F; Capitant, C; Chazallon, C; Descamps, D; Katlama, C; Landman, R; Peytavin, G; Pialoux, G; Yéni, P	1
Gatanaga, H; Goto, K; Honda, H; Honda, M; Kamimura, M; Kikuchi, Y; Matsumura, J; Oka, S; Teruya, K; Tsukada, K	1
Ait-Khaled, M; Barbosa, I; Baril, JG; Cauda, R; Craig, C; Givens, N; Lou, Y; Molina, JM; Nichols, WG; Penco, G; Pialoux, G; Rinaldi, R; Soriano, V; Wire, MB; Yeo, J	1
Clotet, B; Felizarta, F; Gutiérrez, F; Hernández-Quero, J; Lou, Y; Morellon, ML; Nichols, G; Ortega, E; Pérez-Elías, MJ; Pineda, JA; Rodríguez-Torres, M; Wire, MB	1
Atripaldi, L; D'Antonio, A; Perrella, A; Perrella, O; Sbreglia, C	1
Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD	1
Briz, V; de José, MI; de Ory, SJ; González-Tomé, MI; León Leal, JA; Mellado, MJ; Moreno, D; Muñoz-Fernández, MA; Palladino, C; Policarpo, SN; Ramos, JT; Silveira, LF	1
Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N	1
DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG	1
Boccara, F; Costagliola, D; Cotte, L; Gilquin, J; Lang, S; Mary-Krause, M; Partisani, M; Simon, A	1
Bermudez, A; Garb, J; Kronschnabel, D; Martorell, C; Oie, K; Theroux, E	1
Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF	1
Burleson, D; Gayton, JC; Laughlin, RT; Polenakovik, H	1
Cuffe, RL	1
Bogner, JR; Gyalrong-Steur, M; Seybold, U	1
Delgado-Fernández, M; García-Figueras, C; López-Cortés, LF; Macías, J; Márquez-Solero, M; Martínez-Pérez, MA; Mata, R; Merchante, N; Merino, D; Omar, M; Pasquau, J; Pineda, JA; Ríos-Villegas, MJ; Rivero, A	1
Domingo, P; Gutierrez, M; Niubó, J; Podzamczer, D; Saumoy, M; Tiraboschi, J; Vila, A	1
Arribas, JR; Estébanez, M	1
Blick, G; Dupree, D; Garton, T; Greiger-Zanlungo, P; Gretz, S; Han, J; Pakes, GE; Wine, BC; Yau, LH	1
Adorni, F; Galli, M; Giacomet, V; Mameli, C; Rusconi, S; Viganò, A; Viganò, O; Zuccotti, GV	1
Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D	1
Aberg, JA; Castor, D; Cespedes, MS; Ford, SL; Lee, D; Lou, Y; Pakes, GE	1
Chaudry, NI; Eron, JJ; Fiscus, SA; Kashuba, AD; Naderer, OJ; Pereira, AS; Wire, MB	1
Murphy, RL	1
Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J	1
Boghossian, J; Gray, GE; Millard, JM; Nadler, JP; Quinones, AR; Rodriguez-French, A; Sepulveda, GE; Wannamaker, PG	1
Boyle, BA	1
Pham, PA	1
Elston, RC; MacManus, S; Richards, N; Snowden, W; White, S; Yates, PJ	1
Nadler, J	1
DeGoey, DA; Randolph, JT	1
Bellos, NC; DeJesus, E; Garris, C; Gathe, JC; Gladysz, A; Ive, P; Schürmann, D; Wood, R; Yeo, J	1
Becker, S; Thornton, L	1
Chapman, TM; Perry, CM; Plosker, GL	1
Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Higgs, C; Hill, A; Moyle, G; Nelson, M; Pozniak, A	1
Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN	1
Wilkins, E	1
Arvieux, C; Tribut, O	1
James, JS	1
Elston, R; Kleinkauf, N; Schürmann, D; Suttorp, N; Wünsche, T; Xu, F	1
Girault, V	1
Bhatti, L; Farthing, C; Khanlou, H	1
Shelton, MJ; Studenberg, S; Wire, MB	1
Anderson, PL; Fletcher, CV; Kiser, JJ; Lichtenstein, KA	1
Bonora, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Gennari, W; Gerunda, GE; Guaraldi, G; Luzi, K; Masetti, M; Motta, A; Pecorari, M	1
DeJesus, E; Elston, R; Garris, C; Gathe, JC; Givens, N; Gladysz, A; Sanne, I; Schürmann, D; Wood, R; Yeo, J	1
Piacenti, FJ	1
DeJesus, E; Eron, J; Estrada, V; Gathe, J; Katlama, C; Lackey, P; Patel, L; Shaefer, M; Staszewski, S; Sutherland-Phillips, D; Vavro, C; Wannamaker, P; Yau, L; Yeni, P; Yeo, J; Young, B	1
DeJesus, E; Lou, Y; Masterman, A; Min, SS; Piliero, PJ; Shelton, MJ; Stein, DS; Summers, K; Wire, MB	1
Lancaster, CT; Lou, Y; Luber, AD; Pappa, KA; Ruane, PJ; Shelton, MJ; Wire, MB	1
Sax, PE	2
Boucher, S; Breilh, D; Coureau, G; Dabis, F; Fleury, H; Lacoste, D; Lazaro, E; Merel, P; Neau, D; Pellegrin, I; Pellegrin, JL; Saux, MC; Thiébaut, R	1
Arduino, RC; Barnett, BJ; Torres, HA	1
Acosta, EP; Jennings, HC; Parks, DA; Taylor, CW	1
Arduino, RC; Torres, HA	1
Castagna, A; De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Gianotti, N; Lazzarin, A; Schira, G; Seminari, E; Soldarini, A; Uberti-Foppa, C	1
Bacarelli, A; Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Gatti, G; Pinnetti, C; Prosperi, M	1
Brower, R; Frank, I; Kim, D; Luber, AD; Peloquin, CA; Silverman, R	1
Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C	1
Acosta, EP; Easley, KA; Lennox, JL; Ofotokun, I; Pan, Y	1
Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F	1
Delgado, O; Murillas, J; Riera, M; Ventayol, P	1
Antoun, Z; Assoumou, KL; Bocket, L; Brun-Vézinet, F; Charpentier, C; Costagliola, D; Cottalorda, J; Descamps, D; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Peytavin, G; Ruffault, A; Tamalet, C	1
Gatell, JM	1
Corbett, AH; Kashuba, AD	1

Reviews

14 review(s) available for fosamprenavir and HIV Infections

Article	Year
Clinically relevant drug-drug interactions between antiretrovirals and antifungals. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4 Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Echinocandins; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Mycoses; Organophosphates; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Voriconazole	2014
Protease inhibitor monotherapy: what is its role? Current HIV/AIDS reports, 2012, Volume: 9, Issue:2 Topics: Adipose Tissue; Bone Density; Carbamates; Drug Combinations; Drug Resistance, Viral; Furans; HIV Infections; Humans; Lopinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides	2012
Reviving protease inhibitors: new data and more options. Journal of acquired immune deficiency syndromes (1999), 2003, Jun-01, Volume: 33 Suppl 1 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Organophosphates; Pyridines; Pyrones; Sulfonamides	2003
The continuing evolution of HIV therapy. The AIDS reader, 2003, Volume: 13, Issue:12 Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine	2003
Peptidomimetic inhibitors of HIV protease. Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane	2004
Fosamprenavir: advancing HIV protease inhibitor treatment options. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:9 Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Induction; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Prodrugs; Sulfonamides	2004
Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs, 2004, Volume: 64, Issue:18 Topics: Anti-Retroviral Agents; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Infections; Humans; Organophosphates; Sulfonamides	2004
Pharmacokinetics of Telzir (fosamprenavir). Journal of HIV therapy, 2004, Volume: 9, Issue:4 Topics: Anti-HIV Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Organophosphates; Sulfonamides	2004
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs, 2005, Volume: 65, Issue:5 Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides	2005
[The treatment of HIV infection]. Presse medicale (Paris, France : 1983), 2005, Nov-19, Volume: 34, Issue:20 Pt 2 Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Sulfonamides; Tenofovir; Zidovudine	2005
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clinical pharmacokinetics, 2006, Volume: 45, Issue:2 Topics: Adult; Carbamates; Drug Interactions; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Absorption; Organophosphates; Prodrugs; Reverse Transcriptase Inhibitors; Sulfonamides; Tissue Distribution	2006
An update and review of antiretroviral therapy. Pharmacotherapy, 2006, Volume: 26, Issue:8 Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir	2006
Fosamprenavir calcium plus ritonavir for HIV infection. Expert review of anti-infective therapy, 2007, Volume: 5, Issue:3 Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Organophosphates; Ritonavir; Sulfonamides	2007
From amprenavir to GW433908. Journal of HIV therapy, 2001, Volume: 6, Issue:4 Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Furans; HIV Infections; Humans; Organophosphates; Prodrugs; Sulfonamides	2001

Trials

28 trial(s) available for fosamprenavir and HIV Infections

Article	Year
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC infectious diseases, 2013, Jun-07, Volume: 13 Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; C-Reactive Protein; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Furans; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Middle Aged; Organophosphates; Plasminogen; Prospective Studies; Ritonavir; Sulfonamides; Vascular Cell Adhesion Molecule-1; Young Adult	2013
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data. The Pediatric infectious disease journal, 2014, Volume: 33, Issue:1 Topics: Carbamates; Cohort Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2014
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children. The Pediatric infectious disease journal, 2014, Volume: 33, Issue:1 Topics: Adolescent; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Furans; HIV Infections; HIV-1; Humans; Male; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2014
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients. Journal of clinical pharmacology, 2014, Volume: 54, Issue:2 Topics: Adolescent; Carbamates; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Models, Biological; Organophosphates; Prodrugs; Ritonavir; Sulfonamides	2014
Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection. International journal of STD & AIDS, 2008, Volume: 19, Issue:8 Topics: Adult; Anti-HIV Agents; Carbamates; Diarrhea; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease; HIV-1; Humans; Hypertriglyceridemia; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome	2008
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:12 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load	2008
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:1 Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Furans; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypercholesterolemia; Hypertriglyceridemia; Male; Organophosphates; Ritonavir; RNA, Viral; Spain; Sulfonamides; Viral Load; Viremia	2009
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS research and human retroviruses, 2009, Volume: 25, Issue:4 Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult	2009
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:1 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparagine; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Quinolines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load	2009
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:2 Topics: Adult; Aged; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load	2009
Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12 Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Young Adult	2009
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV medicine, 2010, Volume: 11, Issue:3 Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult	2010
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PloS one, 2010, Feb-23, Volume: 5, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome	2010
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. AIDS research and human retroviruses, 2010, Volume: 26, Issue:4 Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure	2010
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men. Antiviral therapy, 2010, Volume: 15, Issue:8 Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir	2010
Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients. AIDS patient care and STDs, 2011, Volume: 25, Issue:7 Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Drug Therapy, Combination; Female; Furans; Hepacivirus; Hepatitis C; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides	2011
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. Journal of acquired immune deficiency syndromes (1999), 2013, Apr-15, Volume: 62, Issue:5 Topics: Adult; Area Under Curve; Carbamates; Disease Transmission, Infectious; Female; Fetal Blood; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Organophosphates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Sulfonamides; Young Adult	2013
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides	2004
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. Journal of acquired immune deficiency syndromes (1999), 2004, Jan-01, Volume: 35, Issue:1 Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organophosphates; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides	2004
GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS (London, England), 2004, Mar-05, Volume: 18, Issue:4 Topics: Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Follow-Up Studies; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Organophosphates; Phenotype; Ritonavir; Sulfonamides	2004
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS (London, England), 2004, Jul-23, Volume: 18, Issue:11 Topics: Adolescent; Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nelfinavir; Organophosphates; Patient Compliance; Ritonavir; Sulfonamides	2004
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS (London, England), 2005, Jan-28, Volume: 19, Issue:2 Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome	2005
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clinical therapeutics, 2006, Volume: 28, Issue:5 Topics: Adult; Aged; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Time	2006
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet (London, England), 2006, Aug-05, Volume: 368, Issue:9534 Topics: Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides	2006
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:9 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides	2006
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2 Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides	2007
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antiviral therapy, 2007, Volume: 12, Issue:6 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides	2007
Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus. Pharmacotherapy, 2008, Volume: 28, Issue:1 Topics: Adult; Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; Half-Life; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides	2008

Other Studies

55 other study(ies) available for fosamprenavir and HIV Infections

Article	Year
Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. Journal of medical virology, 2013, Volume: 85, Issue:5 Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; Carbamates; CD4 Lymphocyte Count; Darunavir; Dyslipidemias; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolome; Middle Aged; Organophosphates; Prospective Studies; Protease Inhibitors; Ritonavir; Sulfonamides; White People	2013
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients. European journal of internal medicine, 2013, Volume: 24, Issue:6 Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine	2013
A reduced grade of liver fibro-steatosis after raltegravir, maraviroc and fosamprenavir in an HIV/HCV co-infected patient with chronic hepatitis, cardiomyopathy, intolerance to nelfinavir and a marked increase of serum creatine phosphokinase levels probab The West Indian medical journal, 2012, Volume: 61, Issue:9 Topics: Adult; Carbamates; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Creatine Kinase; Cyclohexanes; Drug Substitution; Drug Therapy, Combination; Fatty Liver; Furans; Hepatitis C, Chronic; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Maraviroc; Organophosphates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles	2012
Post-licensing safety of fosamprenavir in HIV-infected children in Europe. Pharmacoepidemiology and drug safety, 2014, Volume: 23, Issue:3 Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Cohort Studies; Europe; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Hypercholesterolemia; Male; Organophosphates; Pregnancy; Product Surveillance, Postmarketing; Retrospective Studies; Sulfonamides	2014
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study. HIV clinical trials, 2016, Volume: 17, Issue:3 Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cause of Death; CD4 Lymphocyte Count; Coinfection; Female; Furans; Hepatitis; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Mortality; Organophosphates; Proportional Hazards Models; Recurrence; Retrospective Studies; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load	2016
Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. Antiviral therapy, 2008, Volume: 13, Issue:5 Topics: Adult; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Nelfinavir; Organophosphates; Sulfonamides; Tacrolimus	2008
Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection. Journal of acquired immune deficiency syndromes (1999), 2008, Nov-01, Volume: 49, Issue:3 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lamivudine; Male; Organophosphates; Prospective Studies; Ritonavir; Sulfonamides; Zidovudine	2008
[Individualized therapy with fosamprenavir/r. A PI suitable in liver problems]. MMW Fortschritte der Medizin, 2008, Apr-28, Volume: 150 Spec No 1 Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Furans; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Liver Function Tests; Organophosphates; Ritonavir; Sulfonamides; Viral Load	2008
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. The Journal of antimicrobial chemotherapy, 2009, Volume: 63, Issue:3 Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Carbamates; Chromatography, High Pressure Liquid; Elasticity Imaging Techniques; Female; Furans; Hepatitis C; HIV; HIV Infections; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Organophosphates; Plasma; Sulfonamides; Viral Load	2009
Four posters add to our knowledge of Lexiva. Project Inform perspective, 2008, Issue:47 Topics: Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides	2008
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus. Archives of ophthalmology (Chicago, Ill. : 1960), 2009, Volume: 127, Issue:3 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir	2009
Comment on: Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:1 Topics: Anti-HIV Agents; Carbamates; Furans; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Organophosphates; Sulfonamides	2009
Favourable use of non-boosted fosamprenavir in patients treated with warfarin. International journal of STD & AIDS, 2009, Volume: 20, Issue:6 Topics: Adult; Anti-HIV Agents; Anticoagulants; Atrial Fibrillation; Carbamates; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Japan; Male; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome; Warfarin	2009
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2010, Volume: 16, Issue:6 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-gamma; Interleukin-4; Male; Organophosphates; RNA, Viral; Sulfonamides; Transaminases; Viral Load	2010
Long-term efficacy and safety of fosamprenavir in human immunodeficiency virus-infected pediatric patients. The Pediatric infectious disease journal, 2010, Volume: 29, Issue:6 Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Child; Child, Preschool; Female; Furans; HIV; HIV Infections; HIV-1; Humans; Male; Organophosphates; Retrospective Studies; RNA, Viral; Statistics, Nonparametric; Sulfonamides; Viral Load	2010
Heart attack warning issued. AIDS patient care and STDs, 2010, Volume: 24, Issue:1 Topics: Anti-HIV Agents; Carbamates; Furans; HIV Infections; Humans; Myocardial Infarction; Organophosphates; Sulfonamides	2010
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Archives of internal medicine, 2010, Jul-26, Volume: 170, Issue:14 Topics: Adult; Anti-HIV Agents; Carbamates; Case-Control Studies; Cohort Studies; Confidence Intervals; Dideoxynucleosides; Female; France; Furans; HIV Infections; Hospitals, Isolation; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Organophosphates; Regression Analysis; Risk; Ritonavir; Sulfonamides	2010
Safety and efficacy of fosamprenavir in human immunodeficiency virus-infected pregnant women. The Pediatric infectious disease journal, 2010, Volume: 29, Issue:10 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Organophosphates; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Sulfonamides; Treatment Outcome	2010
Avascular necrosis of the talus in a HIV-infected patient. Foot & ankle international, 2010, Volume: 31, Issue:12 Topics: Adenine; Carbamates; Deoxycytidine; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphates; Organophosphonates; Orthotic Devices; Osteonecrosis; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Talus; Tenofovir	2010
The inclusion of historical control data may reduce the power of a confirmatory study. Statistics in medicine, 2011, May-30, Volume: 30, Issue:12 Topics: Bayes Theorem; Carbamates; Computer Simulation; Control Groups; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Models, Statistical; Organophosphates; Randomized Controlled Trials as Topic; Sulfonamides; Viral Load	2011
Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients. European journal of medical research, 2011, Feb-24, Volume: 16, Issue:2 Topics: Adult; Atazanavir Sulfate; Carbamates; Cholesterol; Cohort Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Retrospective Studies; Saquinavir; Sulfonamides	2011
Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study). HIV medicine, 2011, Volume: 12, Issue:7 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV-1; Humans; Male; Organophosphates; Pilot Projects; Prospective Studies; Ritonavir; RNA, Viral; Spectrum Analysis; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication	2011
Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study. International journal of STD & AIDS, 2012, Volume: 23, Issue:3 Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; Humans; Lipids; Male; Middle Aged; Organophosphates; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load	2012
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population. BMC infectious diseases, 2012, Aug-06, Volume: 12 Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Child; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Oligopeptides; Organophosphates; Pyridines; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load	2012
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. HIV medicine, 2013, Volume: 14, Issue:3 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Furans; HIV Infections; Humans; Italy; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Oxazines; Pyridines; Self Report; Sulfonamides; Surveys and Questionnaires; Viral Load	2013
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-15, Volume: 35, Issue:6 Topics: Adult; Anti-HIV Agents; Carbamates; Chemistry, Pharmaceutical; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Organophosphates; Prodrugs; Ritonavir; Semen; Sulfonamides	2002
SOLO trial results released. AIDS patient care and STDs, 2003, Volume: 17, Issue:2 Topics: Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; Humans; Nelfinavir; Organophosphates; Protease Inhibitors; Ritonavir; Sulfonamides	2003
NEAT trial releases results. AIDS patient care and STDs, 2002, Volume: 16, Issue:12 Topics: Carbamates; Furans; HIV Infections; Humans; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Protease Inhibitors; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome; Viral Load	2002
Viral patterns of unboosted 908 identified. AIDS patient care and STDs, 2003, Volume: 17, Issue:8 Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Mutation; Organophosphates; Prodrugs; Sulfonamides	2003
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load	2003
Drug profile: fosamprenavir (Lexiva). The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2003, Volume: 15, Issue:6 Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides	2003
Fosamprenavir: a new PI option. Interview by Craig Sterritt. IAPAC monthly, 2004, Volume: 10, Issue:2 Topics: Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Reverse Transcriptase Inhibitors; Sulfonamides	2004
[Maintaining independence. New protease inhibitor receives drug approval recommendation]. MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1 Topics: Carbamates; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Europe; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Organophosphates; Sulfonamides; Viral Load	2004
[FPV plus SQV plus a mini-dose ritonavir. "Double boosting with compatible partners]. MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1 Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cross-Over Studies; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Prodrugs; Ritonavir; Saquinavir; Sulfonamides	2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. Journal of acquired immune deficiency syndromes (1999), 2004, Nov-01, Volume: 37, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolic Clearance Rate; Middle Aged; Organophosphates; Ritonavir; RNA, Viral; Saquinavir; Sulfonamides; Viral Load	2004
Lexiva: blood levels not lowered when taken simultaneously with Nexium. AIDS treatment news, 2005, May-27, Issue:412 Topics: Anti-HIV Agents; Carbamates; Drug Administration Schedule; Drug Interactions; Esomeprazole; Furans; HIV Infections; Humans; Organophosphates; Sulfonamides	2005
Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations. AIDS (London, England), 2006, Jan-02, Volume: 20, Issue:1 Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mutation; Organophosphates; Prodrugs; Sulfonamides	2006
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients. Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia	2006
[Long-term virus suppression. Expanding therapy options with protease inhibitor]. MMW Fortschritte der Medizin, 2005, Apr-25, Volume: 147 Spec No 1 Topics: Antiretroviral Therapy, Highly Active; Carbamates; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Long-Term Care; Organophosphates; Sulfonamides; Viral Load	2005
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy, 2006, Volume: 26, Issue:4 Topics: Aged; Anti-HIV Agents; Anti-Ulcer Agents; Atazanavir Sulfate; Carbamates; Drug Interactions; Esomeprazole; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphates; Prospective Studies; Proton Pump Inhibitors; Pyridines; Sulfonamides	2006
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplantation proceedings, 2006, Volume: 38, Issue:4 Topics: Adult; Anti-HIV Agents; Carbamates; Furans; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome	2006
Meeting report. Report from ICAAC. AIDS clinical care, 2006, Volume: 18, Issue:12 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Cyclopropanes; Furans; HIV Infections; Humans; Oligopeptides; Organic Chemicals; Organophosphates; Oxazines; Patient Compliance; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Viral Load	2006
Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Antiretroviral Therapy, Highly Active; Carbamates; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV-1; Humans; Organophosphates; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2007
Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Mar-15, Volume: 44, Issue:6 Topics: Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; Glucosephosphate Dehydrogenase Deficiency; Hemoglobins; HIV Infections; HIV Protease Inhibitors; Humans; Male; Organophosphates; Probability; Retrospective Studies; Risk Factors; Sulfonamides; Treatment Outcome	2007
Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects. AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10 Topics: Adenine; Adolescent; Adult; Antiviral Agents; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome	2007
[Two year use of Telzir: what are the perspectives?]. Medecine et maladies infectieuses, 2007, Volume: 37, Issue:3 Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organophosphates; Phenotype; Ritonavir; Sulfonamides	2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4 Topics: Adult; Anti-HIV Agents; Area Under Curve; Attention; Bilirubin; Carbamates; Chromatography, High Pressure Liquid; Female; Furans; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Plasma; Ritonavir; Sulfonamides; Time Factors	2007
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors. Scandinavian journal of infectious diseases, 2007, Volume: 39, Issue:9 Topics: Adult; Algorithms; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Organophosphates; Prevalence; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides	2007
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV medicine, 2007, Volume: 8, Issue:7 Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Oligopeptides; Omeprazole; Organophosphates; Proton Pump Inhibitors; Pyridines; Sulfonamides	2007
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. Fundamental & clinical pharmacology, 2008, Volume: 22, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides	2008
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26, Issue:3 Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides	2008
Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:6 Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Organophosphates; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2008
Lower dose of ritonavir approved for use with fosamprenavir. AIDS clinical care, 2007, Volume: 19, Issue:12 Topics: Carbamates; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration	2007
FDA notifications. FDA approves NDA for Lexiva. AIDS alert, 2007, Volume: 22, Issue:12 Topics: Carbamates; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Sulfonamides; United States; United States Food and Drug Administration	2007
Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline. Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:3 Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Furans; HIV Infections; Humans; Organophosphates; Structure-Activity Relationship; Sulfonamides	2002